Sanofi is warned by the FDA over ‘significant’ problems at a key manufacturing plant

Taking stock of the drug industry, from the lab to the medicine chest

January 21, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Ruby Wallau for STAT STAT+ | Sanofi is warned by the FDA over 'significant' problems at a key manufacturing plant The Sanofi quality control unit at the plant failed to ensure that active ingredients made there complied with good manufacturing practices. By Ed Silverman Opinion: Three former FDA officials: Here's what Trump and his nominees need to know As former senior FDA officials, we hope that the new Trump leadership will retain three key characteristics of the world-leading agency. By Stuart Pape, Wayne Pines, and Mitch Zeller Trump's initial orders reverse Biden on health care costs, protections from discrimination Trump's executive orders took aim at Biden's priorities, from drug pricing to gender discrimination. By Sarah Owermohle, John Wilkerson, Rachel Cohrs Zhang, and Lizzy Lawrence Adobe STAT+ | Germany's ITM, a stalwart in radiopharmaceuticals, gets ready to take its own shots The German company, a supplier of raw materials to Novartis and others, is awaiting trial results on a handful of its own cancer therapies. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser